Production (Stage)
MediPharm Labs Corp.
LABS.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.89% | 28.18% | 13.29% | 6.03% | 67.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.89% | 28.18% | 13.29% | 6.03% | 67.77% |
| Cost of Revenue | -9.14% | 76.79% | 55.83% | -23.66% | 34.60% |
| Gross Profit | 34.56% | -18.87% | -27.31% | 324.16% | 299.37% |
| SG&A Expenses | -31.07% | 30.95% | -14.24% | -28.19% | 78.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 16.16% | -324.50% | 558.23% | -79.88% | -1,803.70% |
| Total Operating Expenses | -19.67% | 53.06% | 16.74% | -26.41% | 50.77% |
| Operating Income | 87.79% | -130.36% | -31.99% | 68.13% | -16.61% |
| Income Before Tax | 89.93% | 45.18% | 37.00% | 11.98% | -17.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 89.93% | 39.81% | 36.96% | 11.98% | -17.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 89.93% | 39.81% | 36.96% | 11.98% | -17.31% |
| EBIT | 87.79% | -130.36% | -31.99% | 68.13% | -16.61% |
| EBITDA | 99.17% | -91.68% | -55.40% | 75.25% | -7.46% |
| EPS Basic | 90.91% | 44.44% | 39.51% | 14.55% | 19.51% |
| Normalized Basic EPS | 89.47% | -111.11% | -15.38% | 70.00% | 15.56% |
| EPS Diluted | 90.91% | 44.44% | 39.51% | 14.55% | 19.51% |
| Normalized Diluted EPS | 89.47% | -111.11% | -15.38% | 70.00% | 15.56% |
| Average Basic Shares Outstanding | 2.83% | 9.01% | 3.15% | 4.26% | 45.81% |
| Average Diluted Shares Outstanding | 2.83% | 9.01% | 3.15% | 4.26% | 45.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |